Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor thera...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Public Library of Science (PLoS)
2018-09-01
|
| Rangatū: | PLoS Genetics |
| Urunga tuihono: | https://hdl.handle.net/10923/21647 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|